Transfusion-acquired cytomegalovirus infection approaching resolution

Blood Safety and Surveillance

Volumn , Issue , 2016, Pages 316-333

  Tegtmeier, Gary E ^a  

^a Division of New York Blood Center Enterprises   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 32644459382     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (85)

1. Ho M, Cytomegalovirus: Biology and Infection. 2nd ed. New York: Plenum, 1991.
2. Kaariainen L, Klemola E, Paloheimo J. Rise of cytomegalovirus antibodies in an infectious mononucleosis-like syndrome after transfusion. Br Med J 1966; 1:1270-1272.
3. Yeager AS, Grumet FC, Hafleigh EB, Arvin AR, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981; 98:281-287.
4. Ho M, Suwansirikul S, Dowling JN, Youngblood LA, Armstrong JA. The transplanted kidney as a source of cytomegalovirus infection. N Engl J Med 1975; 293:1109-1112.
5. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153:478-488.
6. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Meyers JD. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314:1006-1010.
7. Mackinnon S, Burnett AK, Crawford RJ, Cameron S, Leask BG, Sommerville RG. Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation. J Clin Pathol 1988; 41:948-950.
8. Miller WJ, McCullough J, Balfour HH Jr, Haake RJ, Ramsay NK, Goldman A, Bowman R, Kersey J. Prevention of cytomegalovirus-infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991; 7:227-234.
9. Brady MT, Milam JD, Anderson DC, Hawkins EP, Speer ME, Seavy D, Bijou H, Yow MD. Use of deglycerolized red blood cells to prevent posttransfusion infection with cytomegalovirus in neonates. J Infect Dis 1984; 150:334-339.
10. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 79:246-250.
11. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W. A comparison of filtered leukocytereduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86:3598-3603.
12. Mocarski Jr. ES. Cytomegaloviruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Virology. Philadelphia: Lippincott, Raven, 1996:2447-2492.
13. Taylor-Wiedeman J, Sissons JGP, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 1991; 72:2059-2064.
14. Söderberg-Nauclér C, Fisk KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1977; 91:119-126.
15. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci 1998; 95:3937-3942.
16. Slobedman B, Mocarski ES. Quantitative analysis of latent human cytomegalovirus. J Virol 1999; 78:4806-4812.
17. Diosi P, Moldovan E, Tomescu N. Latent cytomegalovirus infection in blood donors. Br Med J 1969; 4:660-662.
18. Beneke JS, Tegtmeier GE, Alter JH, Luetkemeyer RB, Solomon R, Bayer WL. Relation of titers of antibodies to CMV in blood donors to the transmission of cytomegalovirus infection. J Infect Dis 1984; 150:883-888.
19. Lamberson Jr. HV, McMillan JA, Weiner LB, Williams ML, Clark DA, McMahon CA, Lentz EB, Higgins AP, Dock NL. Prevention of transfusion-associated cytomegalovirus (CMV) infection in neonates by screening blood donors for IgM to CMV. J Infect Dis 1988; 157:820-823.
20. Revello MG, Zavattoni M, Sarasini A, Percivalle E, Simoncini L, Gerna G. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis 1998; 177:1170-1175.
21. Zhanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999; 180:702-707.
22. Tegtmeier GE, Henderson SE, Blosser JK, Drew WL, Miner R. CMV DNA in plasma of seroconverting and anti-CMV seroprevalent blood donors (abstract). Transfusion 1999; 39:116S.
23. Stanier P, Taylor DL, Kitchen AD, Wales N, Tryhorn Y, Tyms AS. Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors. Br Med J 1989; 299:897-898.
24. Bevan IS, Daw RA, Day PJ, Ala FA, Walker MR. Polymerase chain reaction for detection of human cytomegalovirus infection in a blood donor population. Br J Haematol 1991; 78:94-99.
25. Larsson S, Soderberg-Nauclér C, Wang FZ, Moller E. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion 1998; 38:271-278.
26. Bitsch A, Kirchner H, Dupke R, Bein G. Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction. Transfusion 1992; 32:612-617.
27. Nolte FS, Emmens RK, Thurmond C, Mitchell PS, Pascuzzi C, Devine SM, Saral R, Wingard JR. Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification. J Clin Microbiol 1995; 33:1263-1266.
28. Roback JD, Hillyer CD, Drew WL, Luka J, Mocarski ES, Soderberg-Naucler C, Woxenius S, Busch MP. Comparison of 7 PCR assays for detection of cytomegalovirus (CMV) DNA in PBMCS of blood donors: results of a blinded multicenter study (abstr). Blood 1999; 94:246a.
29. Winston DJ, Ho WG, Howell CL, Miller MJ, Mickey R, Martin WJ, Lin CH, Gale RP. Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med 1980; 93:671-675.
30. Hersman J, Meyers JD, Thomas ED, Buckner CD, Clift R. The effect of granulocyte transfusions on the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med 1982; 96:149-152.
31. Luthardt T, Siebert H, Lösel I, Quevedo M, Todt R. Cytomegalovirus-infektionen bei Kindern mit Blutaustausch-transfusion im Neugeborenenalter. Klin Wochenschr 1971; 49:81-86.
32. Bowden R, Sayers M. The risk of transmitting cytomegalovirus infection by fresh frozen plasma. Transfusion 1990; 30:762-763.
33. Wilhelm JA, Matter L, Schopfer K. The risk of transmitting cytomegalovirus to patients receiving blood transfusion. J Infect Dis 1986; 154:169-171.
34. Preiksaitis JK, Brown L, McKenzie M. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis 1988; 157:523-529.
35. Adler SP, Chandrika T, Lawrence L, Baggett J. Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr Infect Dis 1983; 2:114-118.
36. Smith D Jr, Wright P, Estes W, Krueger L, Wallas C, Moldovan R, Tanley P. Posttransfusion cytomegalovirus infection in neonates weighing less than 1250 grams (abstr). Transfusion 1983; 23:420.
37. Tegtmeier GE. The use of cytomegalovirus-screened blood in neonates. Transfusion 1988; 28:201-203.
38. Preiksaitis JK, Brown L, McKenzie M. Transfusion-acquired cytomegalovirus infection in neonates. A prospective study. Transfusion 1988; 28:205-209.
39. Stagno S. Cytomegalovirus. In: Remington J, Klein G, eds. Infectious Diseases of the Fetus and Newborn. Philadelphia: WB Saunders, 1995:312-353.
40. Marker SC, Howard RJ, Simmons RL, Kalis JM, Connelly DP, Najarian JS, Balfour Jr. HM. Cytomegalovirus infection: A quantitative prospective study of three hundred consecutive renal transplants. Surgery 1981; 89:660-671.
41. Harris KR, Saeed AA, Digard NJ, Whiteford K, Geoghegan TA, Lee HA, Slapak M. Cytomegalovirus titers in kidney transplant donor and recipient: influence of cyclosporine A. Transplant Proc 1984; 16:31-33.
42. Rubin RH, Tolkoff-Rubin NE, Oliver R, Rota TR, Hamilton J, Betts RF, Pass RF, Hillis W, Szmuness W, Farrel ML, Hirsch MS. Multi-center seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation 1985; 40:243-249.
43. Boyce NW, Hayes K, Gee D, Holdsworth SR, Thomson NM, Scott D, Atkins RC. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy. Transplantation 1988; 45:706-709.
44. Chou S, Norman DJ. The influence of donor factors other than serologic status on transmission of cytomegalovirus to transplant recipients. Transplantation 1988; 46:89-93.
45. Preiksaitis JK, Rosno S, Grumet C, Merigan TC. Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. J Infect Dis 1983; 147:974-981.
46. Wreghitt TG, Hakim M, Gray JJ, Kucia S, Wallwork J, English TA. Cytomegalovirus infections in heart and heart and lung transplant recipients. J Clin Pathol 1988; 41:660-667.
47. Dummer JS, Montero CG, Griffith BP, Hardesty RL, Paradis IL, Ho M. Infections in heart-lung transplant recipients. Transplantation 1986; 41:725-729.
48. Wreghitt T. Cytomegalovirus infections in heart and heart-lung transplant recipients. J Anti-Microb Chem 1989(suppl E); 23:49-60.
49. Smyth RL, Scott JP, Borysiewicz LK, Sharples LD, Steart S, Wreghitt T, Gray JJ, Higenbottam TW, Wallwork J. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations and response to treatment. J Infect Dis 1991; 164:1045-1050.
50. Singh N, Dummer JS, Kusne S, Breinig MK, Armstrong JA, Makowka L, Starzl TE, Ho M. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158:124-131.
51. Barkholt LM, Ericzon B-G, Ehrnst A, Forsgren M, Anderson JP. Cytomegalovirus infections in liver transplant patients: incidence and outcome. Transplant Proc 1990; 22:235-237.
52. Gorensek MJ, Carey WD, Vogt D, Goormastic M. A multivariate analysis of risk factors for cytomegalovirus infection in liver transplant recipients. Gastroenterology 1990; 98:1326-1332.
53. Pillay D, Charman H, Burroughs AK, Smith M, Rolles K, Griffiths PD. Surveillance for CMV infections in orthotopic liver transplant recipients. Transplantation 1992; 53:1261-1265.
54. Sutherland S, Bracken P, Wreghitt TG, O'Grady J, Calne R, Williams R. Donated organ as a source of cytomegalovirus in orthotopic liver transplantation. J Med Virol 1992; 37:170-173.
55. Manez R, Kusne S, Martin M, Linden P, Irish W, Torre-Cisneros J, Kramer D, Ho M, Starzl TE. The impact of blood transfusion on the occurrence of pneumonitis in primary cytomegalovirus infection after liver transplantation. Transfusion 1993; 33:594-597.
56. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG. Primary cytomegalovirus infection in liver transplant recipients: comparison of infections transmitted via donor organs and via transfusions. Clin Infec Dis 1996; 23:292-297.
57. Cox F, Hughes WT. Cytomegaloviremia in children with acute leukemia. J Pediatr 1975; 87:190-194.
58. Murphy MF, Grint PC, Hardiman AE, Lister TA, Waters AH. Use of leukocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukemia (letter). Br J Haematol 1988; 70:253-254.
59. Preiksaitis JK, Desai S, Vaudry W, Roberts S, Akabutu J, Grundy P, Wilson B, Boshkov L, Hannon J, Joffres M. Transfusion-and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study. Transfusion 1997; 37:941-946.
60. American Association of Blood Banks, Association Bulletin #97-2, Leukocyte reduction for the prevention of TA cytomegalovirus. Bethesda, MD: American Association of Blood Banks, 1997.
61. Monif GRG, Daicoff GI, Flory LF. Blood as a potential vehicle for the cytomegaloviruses. Am J Obstet Gynecol 1976; 126:445-448.
62. Yeager AS, Palumbo PE, Malachowski N, Ariagno RL, Stevenson DK. Sequelae of maternally derived cytomegalovirus infections in premature infants. J Pediatr 1983; 102:918-922.
63. Phipps PH, Gregoire L, Rossier E, Perry E. Comparison of five methods of cytomegalovirus antibody screening of blood donors. J Clin Microbiol 1983; 18:1296-1300.
64. Beckwith DG, Halstead DC, Alpaugh K, Schweder A, Blount-Fronefield DA, Toth K. Comparison of a latex agglutination test with five other methods for determining the presence of antibody against cytomegalovirus. J Clin Microbiol 1985; 21:328-331.
65. Adler SP, McVoy M, Biro VG. Detection of cytomegalovirus antibody with latex agglutination. J Clin Microbiol 1985; 22:68-70.
66. Taswell HF, Reisner RK, Rabe DE, Shelley CD, Smith TF. Comparison of three methods for detecting antibody to cytomegalovirus. Transfusion 1986; 26:285-289.
67. Waner JL, Weller TH, Kevy SV. Patterns of cytomegalovirus complement fixing antibody activity: A longitudinal study of blood donors. J Infect Dis 1973; 127:538-543.
68. Canadian Blood Services, Canadian Blood and Marrow Transplant Group, Consensus Conference: Prevention of Post-Transfusion CMV in the Era of Universal Leukoreduction, Toronto, Canada, January 7-8, 2000.
69. Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull WHO 1973; 49:103-106.
70. Tegtmeier GE. Transfusion-transmitted cytomegalovirus infections: significance and control. Vox Sang 1986; 51(suppl1):22-30.
71. Lang DJ, Ebert PA, Rodgers BM, Boggess HP, Rixse RS. Reduction of postperfusion cytomegalovirus infections following the use of leukocyte-depleted blood. Transfusion 1977; 17:391-395.
72. Tolkoff-Rubin NE, Rubin RH, Keller EE, Baker GP, Stewart JA, Hirsch MS. Cytomegalovirus infection in dialysis patients and personnel. Ann Intern Med 1978; 89:625-628.
73. Demmler GJ, Brady MT, Bijou H, Speer ME, Milam JD, Hawkins EP, Anderson DC, Six H, Yow MD. Posttransfusion cytomegalovirus infection of neonates: role of saline-washed red blood cells. J Pediatr 1986; 108:762-765.
74. Luban NL, Williams AE, MacDonald MG, Mikesell GT, Williams KM, Sacher RA. Low incidence of cytomegalovirus infection in neonates transfused with washed red blood cells. Am J Dis Child 1987; 141:416-419.
75. Gilbert GL, Hayes K, Hudson IL, James J. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes. Lancet 1989; 2:1228-1231.
76. Eisenfeld L, Silver H, McLaughlin J, Klevjer-Anderson P, Mayo D, Anderson J, Herson V, Krause P, Savidakis J, Lazar A. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 1992; 32:205-209.
77. de Graan-Hentzen YC, Gratama JW, Mudde GC, Verdonck LF, Houbiers JG, Brand A, Sebens FW, van Loon AM, The TH, Willemze R. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 1989; 29:757-760.
78. De Witte T, Schattenberg A, Van Dijk BA, Galama J, Olthuis H, Van der Meer JW, Kunst VA. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood bank donors. Transplantation 1990; 50:964-968.
79. van Prooijen HC, Visser JJ, van Oostendorp WR, de Gast GC, Verdonck LF. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol 1994; 87:144-147.
80. Pamphilon DH, Rider JR, Barbara JA, Williamson LM. Prevention of transfusiontransmitted cytomegalovirus infection. Transf Med 1999; 9:115-123.
81. Ledent E, Berlin G. Inadequate white cell reduction from red cell concentrates by filtration. Transfusion 1994; 34:765-768.
82. Bodensteiner D. White cell reduction in blood donors with sickle trait (letter). Transfusion 1994; 34:84.
83. Ould Amar AK, Cesaire R, Kérob-Bauchet B, Robert P, Maier H, Bucher B. Altered filterability of fresh sickle trait donor blood (letter). Vox Sang 1997; 73:55-56.
84. Centers for Disease Control and Prevention. Adverse ocular reactions following transfusion-United States, 1997-1998. MMWR 1998; 47:49-50.
85. Nichols G. Is leukoreduction a suitable alternative to CMV screening? Are there alternate methods? Canadian Blood Services, Canadian Blood and Marrow Transplant Group Consensus Conference, Prevention of Post-Transfusion CMV in the Era of Universal Leukoreduction, Toronto, Canada, January 7-8, 2000.